SG&A Efficiency Analysis: Comparing Pfizer Inc. and TG Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Pfizer Inc. and TG Therapeutics, Inc. have demonstrated contrasting approaches to SG&A efficiency.

Pfizer Inc.: A Steady Giant

From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually. This consistency reflects Pfizer's robust operational strategies and its ability to maintain efficiency despite market fluctuations.

TG Therapeutics, Inc.: A Rising Contender

In contrast, TG Therapeutics has seen a significant increase in SG&A expenses, growing from approximately $24 million in 2014 to over $122 million in 2023. This 400% rise indicates aggressive expansion and investment in marketing and administrative capabilities.

Conclusion

While Pfizer's stability showcases its established market presence, TG Therapeutics' growth highlights its ambition to capture a larger market share. Both strategies offer valuable insights into managing SG&A expenses in the pharmaceutical industry.